A. G. Van Den Bos
Research Subjects
Research Interests
A. G. Van Den Bos has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
A. V. M. B. Schattenberg
Department of Haematology, University Medical Centre, St Radboud, Nijmegen, The Netherlands
1 shared publicationB E De Pauw
1 shared publicationB. E. de Pauw
1 shared publication- Jan M. Werre
From the Department of Clinical Chemistry, Rijnstate Hospital, Arnhem; Department of Blood Transfusion and Transplantation Immunology and Department of Biochemistry, Nijmegen Center for Molecular Life Sciences, University Medical Center Nijmegen; and Division of Biopharmaceutics, Leiden University, Leiden, The Netherlands
1 shared publication K. Steiner
Department of Neonatology, University Medical Centre Nijmegen, the Netherlands
1 shared publicationW. M. Wissink
Department of Blood Transfusion and Transplantation Immunology, University Medical Centre, St Radboud, Nijmegen, The Netherlands
1 shared publication
Latest Publications
- 1 October 2004
- Published by Wiley in Vox Sanguinis
- Vol. 87 (3) , 208-209
Haemolytic disease of the newborn caused by anti‐MUT (MNS 35)
- 1 October 2004
- Published by Wiley in Vox Sanguinis
- Vol. 87 (3) , 208-209
Haemolytic disease of the newborn caused by anti‐MUT (MNS 35)
- 20 May 2003
- Published by Wiley in Clinical and Laboratory Haematology
- Vol. 25 (3) , 173-178
Feasibility of a new in vitro approach to evaluate cellular damage following co-infusion of red blood cell concentrates and intravenous drug solutions
Transfusion guidelines may result in unwanted delay in infusion schemes, as simultaneous infusion of blood components and drug solutions is universally prohibited. The aim of this study was to measure possible damage to red cells by drug solutions, as manifested by haemolysis, using a dynamic model that resembles the clinical setting. Stored filtered and irradiated RBC concentrates and drug solutions were co-infused in an in vitro dynamic model. Also, incubation in a static model was performed. The haemolytic potency of the drug solutions was measured by determining free haemoglobin (fHb) levels. Neither in the dynamic tests nor in the static tests did fHb levels exceed the maximally acceptable standard for filtered RBC concentrates according to Dutch specification guidelines. In the static test model, fHb levels were slightly elevated compared with those of control samples, as well as those in the dynamic test model. A novel in vitro dynamic infusion system appears to represent a useful technique to calculate possible damage to RBCs resulting from co-infused drug solutions. Co-infusion of the drug solutions tested with filtered and irradiated RBC concentrates did not produce fHb levels above the levels accepted by the Dutch national guidelines. Apart from haemolysis, other parameters reflecting RBC damage should be investigated in future studies.
- 20 May 2003
- Published by Wiley in Clinical and Laboratory Haematology
- Vol. 25 (3) , 173-178
Feasibility of a new in vitro approach to evaluate cellular damage following co-infusion of red blood cell concentrates and intravenous drug solutions
Transfusion guidelines may result in unwanted delay in infusion schemes, as simultaneous infusion of blood components and drug solutions is universally prohibited. The aim of this study was to measure possible damage to red cells by drug solutions, as manifested by haemolysis, using a dynamic model that resembles the clinical setting. Stored filtered and irradiated RBC concentrates and drug solutions were co-infused in an in vitro dynamic model. Also, incubation in a static model was performed. The haemolytic potency of the drug solutions was measured by determining free haemoglobin (fHb) levels. Neither in the dynamic tests nor in the static tests did fHb levels exceed the maximally acceptable standard for filtered RBC concentrates according to Dutch specification guidelines. In the static test model, fHb levels were slightly elevated compared with those of control samples, as well as those in the dynamic test model. A novel in vitro dynamic infusion system appears to represent a useful technique to calculate possible damage to RBCs resulting from co-infused drug solutions. Co-infusion of the drug solutions tested with filtered and irradiated RBC concentrates did not produce fHb levels above the levels accepted by the Dutch national guidelines. Apart from haemolysis, other parameters reflecting RBC damage should be investigated in future studies.
- 2 September 2000
- Vol. 144 (36) , 1754-6
[Leukocyte depletion of blood products: a requirement for improvement of quality and safety].
- 2 September 2000
- Vol. 144 (36) , 1754-6
[Leukocyte depletion of blood products: a requirement for improvement of quality and safety].